|
The document discusses the results of a study on C-8 (PFOA) that indicates a dose-dependent increase in Leydig cell adenomas in male rats, suggesting hormonal mediation in tumor induction, while also referencing the status of a 3M study assessing liver effects.
|
2009 |
AR226-2009
|
Rpdd38yYLR35NLR135zDM8q3B |
3 |
|
The document summarizes a review of personnel air monitoring and blood data related to C-8 (PFOA) exposure at Washington Works, indicating a correlation between air levels and blood levels, as well as skin contact, with non-compliance observed in jobs with high blood levels.
|
2008 |
AR226-2008
|
zdYo02rY6GDXaz0dnndQEDg4m |
8 |
|
The document reports the results of PFOA serum testing conducted by DuPont and Exygen on twelve individuals from a community near DuPont's Washington Works facility, revealing that all participants were exposed to PFOA through contaminated drinking water averaging approximately 0.5 ppb.
|
2007 |
AR226-1863
|
k61a6no2VavLrwzQrKj6Y37Kb |
3 |
|
The document provides the results of PFOA serum testing for twelve individuals from a community near DuPont's Washington Works facility, indicating exposure to PFOA through contaminated drinking water with an average concentration of approximately 0.5 ppb.
|
2007 |
AR226-1870
|
qde9LQ6x15M8xXkZbzj4Y76ME |
3 |
|
The document is a correspondence from Robert A. Bilott to the EPA, enclosing a letter from DuPont that provides new data on human health effects related to exposure to PFOA, requesting its inclusion in the administrative record AR-226 and OPPT-2003-0012.
|
2007 |
AR226-1886
|
1535Vb2p0z40a42ZwgxED53b5 |
1 |
|
This document is a correspondence from Taft, Stettinius & Hollister LLP to the EPA, providing additional information on a PFOA human health effects study related to cancer data from individuals exposed to PFOA-contaminated drinking water near E.I. duPont de Nemours and Company's facility in West Virginia.
|
2007 |
AR226-1893
|
GmEw4DOorNQ4Dr6wqyDxYy8rn |
2 |
|
This document is a correspondence from Taft, Stettinius & Hollister LLP to the EPA, providing two sets of slides from DuPont regarding preliminary results of a human health effects study on PFOA among workers at the Washington Works Plant in West Virginia.
|
2007 |
AR226-1922
|
N2kDjjeXgRR1vjJDVGdY9yVjD |
2 |
|
This document is a correspondence from Taft, Stettinius & Hollister LLP to the EPA, providing additional detailed summaries of a human health effects study related to PFOA exposure from contaminated drinking water near the E.I. duPont de Nemours and Company's Washington Works Plant.
|
2007 |
AR226-1925
|
V3nvVQ3B62Qpjgbz9eXBnvez8 |
2 |
|
This document is a correspondence from Taft, Stettinius & Hollister LLP regarding a lawsuit against 3M Company related to residential exposure to perfluorochemicals, specifically PFOS and PFOA, due to their manufacturing and disposal practices in Cottage Grove, Minnesota.
|
2007 |
AR226-1955
|
2JNe4vkO4QZ3ZqDoQR3yn0kmb |
8 |
|
The document presents personal air monitoring data from the Washington Works facility, indicating PFOA levels in the Polymers Area, with a mean concentration of 0.09 ppb and a maximum of 0.56 ppb, suggesting the need for further data collection in several instances.
|
2007 |
AR226-2007
|
6wDJN740m0XRMnjwb7oOxL7BE |
2 |
|
The memorandum outlines the temporary assignment of Pamm Mackey to conduct additional C-8 monitoring for perfluorinated compounds, specifically focusing on personal sampling for workers in various roles, with a deadline to complete the data collection by May 1.
|
2006 |
AR226-2006
|
6bOw08VVe6rngJLz0pN3DKkR6 |
2 |
|
This letter reports the results of a study on serum PFOA levels among employees at DuPont's Washington Works plant, indicating a median serum PFOA level of 0.5 ppm for those working with PFOA and noting modest increases in cholesterol fractions and triglycerides in the highest exposure group, while most health parameters remained within normal ranges.
|
2005 |
AR226-1899
|
Z8p80gKR143oXbX5DoeKVZjxV |
2 |
|
3M submitted additional data on perfluorooctane sulfonate (PFOS), perfluorooctanoic acid (PFOA), and related compounds to the EPA as part of their ongoing dialogue regarding perfluorochemicals.
|
2005 |
AR226-1900
|
Ev389oxEooM5RGELp8Myr76px |
2 |
|
This is a letterhead cover page from DuPont regarding a CBI information meeting scheduled for January 31, 2005, with no analytical content retained in the OCR.
|
2005 |
AR226-1911
|
6bj61RzDg1Mk0m7ozvj680yY4 |
1 |
|
The document is a presentation given to the US EPA by DuPont on January 31, 2005, discussing the reduction of Perfluorooctanoic Acid (PFOA), its precursors, and related impurity levels in fluorotelomer intermediates and finished products, with the majority of the content classified as TSCA Confidential Business Information (CBI).
|
2005 |
AR226-1912
|
4J84R4vpEmXaOdebEgbrkmJ2V |
1 |
|
This document is a letter from Martha L. Rees, Associate General Counsel at DuPont, addressing Ms. Mary Dominiak regarding the submission of information related to PFOA and its environmental implications.
|
2005 |
AR226-1913
|
1QRBExEpGbB9gZYXMxLJNk715 |
1 |
|
The document reports on the results of the PFOA Worker Health Study, indicating that while no human health effects have been definitively linked to PFOA, significant associations were found between high serum PFOA levels and certain health measures, prompting further investigation by DuPont and external experts.
|
2005 |
AR226-1923
|
YGdnrroapRvMg1Ya9LzjyVkBk |
24 |
|
The document outlines the preliminary results of a PFOA worker study conducted by DuPont, focusing on the health status of employees at a polymer production plant and their serum PFOA levels, with 1,024 participants involved in the cross-sectional health surveillance.
|
2005 |
AR226-1924
|
jyKjK6eMZGOyXqNrEE4aG8omy |
35 |
|
The January 2005 Supplemental Notice of Contamination from the Little Hocking Water Association reports rising levels of C8 (PFOA) in their water supply, with concentrations reaching up to 18.6 ppb, which exceed Minnesota's safe level of 7.0 ppb, and warns that well no. 5 may need to be activated if water demands increase.
|
2005 |
AR226-1927
|
KGD5oD5naRE58q4dYxo2jZoMx |
3 |
|
3M submitted a TSCA Section 8(e) Supplemental Notice reporting that water samples from municipal wells in Cottage Grove, Hastings, and Oakdale, Minnesota, showed no detectable levels of PFOS and PFOA, except for one sample from Hastings with PFOA below quantification limits, while Oakdale wells had detectable levels of both substances but averaged below 1 ppb.
|
2005 |
AR226-1929
|
XR257b2xGDnenxbLynwNJ6amK |
2 |
|
This document details the data validation process for PFOS and PFOA analysis in samples from the Oakdale Project, confirming that samples were received in good condition, analyzed within acceptable time frames, and met calibration standards with method detection limits of 0.100 ppb for PFOS and 0.097 ppb for PFOA.
|
2005 |
AR226-1936
|
rBbjMqVjxmE3DyEgKrvNkEZyr |
4 |
|
The document presents the results of a survey conducted by the OECD on the production and use of PFOA, PFOS, PFAS, and related substances, detailing their prevalence in products and mixtures.
|
2005 |
AR226-1937
|
RpNZ0VjoGYyGqDN2evj3wNGm8 |
59 |
|
This document is a letter from DuPont Haskell Laboratory informing the EPA about the results of an absorption, distribution, metabolism, and elimination (ADME) study of 1-Decanol, 3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-heptadecafluoro (CAS
|
2005 |
AR226-1941
|
0KZ1q7gzDVwO8Vg4a0apobeJ |
3 |
|
3M is submitting a supplemental notice to the EPA regarding final analytical reports of water samples for sulfonate-based and carboxylic-based fluorochemicals, including PFOA and PFOS, from municipal wells in Hastings and Oakdale, Minnesota.
|
2005 |
AR226-1945
|
Z44vZG5xpj5waELMLdjJ4vBZJ |
1 |
|
3M is submitting a supplemental notice to the EPA regarding final analytical reports for water samples taken from municipal wells in Hastings and Oakdale, Minnesota, related to sulfonate-based and carboxylic-based fluorochemicals.
|
2005 |
AR226-1949
|
V3nLb2kooOKN5nw6O0VOVdYbg |
1 |
|
The document is an analytical report from Exygen Research detailing the analysis of perfluorooctanoate (PFOA) and perfluorooctanesulfonate (PFOS) in water samples collected from Hastings Municipality at the request of Gary A. Hohenstein from 3M Company.
|
2005 |
AR226-1948
|
bB816VBMYywzqJOMxMdepaZaD |
15 |
|
3M submitted a final report on a follow-up incidence study related to perfluorooctanesulfonyl fluoride (POSF) to investigate findings from a previous mortality study of employees at its fluorochemical manufacturing facility.
|
2005 |
AR226-1953
|
J8Ev1aXoarRdz1GepkKqNXdB |
1 |
|
The Minnesota Pollution Control Agency reports that four private wells in Lake Elmo have tested above health-based criteria for perfluorochemicals (PFCs), prompting the agency to provide bottled water and install granular activated carbon filters for affected homes while investigating the Washington County Landfill as a potential source of contamination.
|
2005 |
AR226-1956
|
vBVNKDjdMo47oy8M5mBwD5bVE |
8 |
|
The document is an analysis report from AXYS Analytical Services detailing the detection of various perfluorinated compounds, including PFOA and PFOS, in serum samples collected on February 3, 2005, with specific concentrations reported for each compound.
|
2005 |
AR226-1958
|
QM3oj7JBQ4RgyQ76ko87DzGNv |
63 |
|
This document is a correspondence from Teri K. Fick of 3M to the EPA, providing clarification and resubmission of a final report on a mortality study related to perfluorooctanesulfonyl fluoride (POSF) that was previously submitted but not found in the TSCA 8(e) file.
|
2005 |
AR226-1963
|
2qYaQJ60xvV18v7QnZ32Rd15 |
37 |
|
This is a memo from H. A. Smith to Bob Lanyon regarding recommendations for selecting individuals for blood monitoring at Washington Works, outlining criteria for selection based on job tenure and stability.
|
2005 |
AR226-2005
|
nm8gNY9M1k93rvxO5vQ11o8q8 |
25 |
|
The document outlines the agenda for a meeting between DuPont, 3M, and the EPA on August 25, 2004, focusing on the review of worker exposure data and biological studies related to perfluorinated compounds.
|
2004 |
AR226-1838
|
3Ea8rzX4omzmYxL1jEg8X0L6 |
2 |
|
3M submitted a corrected version of final reports for reproductive avian toxicity studies on perfluorooctanesulfonate (PFOS) in northern bobwhite quail and mallard duck to the EPA, addressing issues of illegibility and omissions from a prior submission.
|
2004 |
AR226-1839
|
qm9522Q7jRG6Q3MmVBD6M2yjK |
3 |
|
The document is an index of TSCA Section 8(e) docket submissions by 3M Company, detailing various pilot, acute, and definitive studies on the toxicological effects of Potassium Perfluorooctanesulfonate (PFOS) on Northern Bobwhite Quail and Mallard Ducks, including methods for extraction and analysis using HPLC-Electrospray/Mass Spectrometry.
|
2004 |
AR226-1840
|
DGNwy4EpR7gN1Vjx0qeQL1eRQ |
2 |
|
3M reported to the EPA that preliminary data from an acute inhalation toxicity study on methyl perfluoroisobutyrate indicated neurotoxicity in rats exposed to 3000 ppm, while no adverse effects were observed at 300 ppm.
|
2004 |
AR226-1862
|
a1aBbX1j7DDjM48m8G5GeyrOa |
2 |
|
The document is an analytical report from Exygen Research detailing the analysis of perfluorooctanoic acid (PFOA) in human serum samples received from Dr. Marsha Bailey, indicating that twelve samples were analyzed using high-pressure liquid chromatography and mass spectrometry methods.
|
2004 |
AR226-1864
|
EvB48q7k4ByKmDwz5jam07mNx |
10 |
|
This document is a letter from Edward E. Shea representing MIC Specialty Chemicals, Inc., submitting a report regarding biological monitoring of workers exposed to perfluorooctanoic acid (PFOA) from Miteni S.p.A. to the EPA, indicating that the information appears favorable but is submitted as a precautionary measure.
|
2004 |
AR226-1865
|
rx9161YyXpEYKXk3NKK40y9Eq |
1 |
|
The document reports on a meeting held in August 2004 between representatives from 3M, DuPont, and Miteni to discuss the analysis of data collected on workers exposed to PFOA at the Miteni plant, emphasizing the importance of this data for understanding PFOA's interaction with human physiology.
|
2004 |
AR226-1866
|
da196pkRnRBLQDzvprExjgrq0 |
8 |
|
This document is a letter submitted to the EPA by DuPont regarding a meeting about the health effects of Ammonium Perfluorooctanoate (PFOA) on workers at the Miteni plant, noting no significant health effects but higher serum levels of PFOA compared to general population levels, and indicating a need for further analysis of observed lipid level changes.
|
2004 |
AR226-1867
|
e5bj7GBw0QxebOeOo5YJBeVky |
2 |
|
This document reports the results of an oral repeated dose toxicity study conducted by DuPont on PFOA in rats and mice, indicating that all test materials (linear, branched, and a mixture) caused similar biological responses, including increased liver weights and changes in lipid chemistry, with mortality observed in one mouse at the highest dose of the linear form.
|
2004 |
AR226-1872
|
y2MZ0GBBOYwreXZ3orne8MMn |
1 |
|
The document is a submission to the EPA under TSCA Section 8(e) by a company providing worker monitoring data on blood levels of perfluorooctanoic acid (PFOA), perfluorononanoic acid (PFNA), and perfluorodecanoic acid (PFDA) from 281 workers at their facility, while arguing that the data does not constitute "
|
2004 |
AR226-1873
|
npqJ6529yeQ7bqda724oE95mz |
5 |
|
This document is a supplemental submission to the EPA regarding a toxicology study conducted by 3M on dermal contact absorption of PFOS (perfluorooctanesulfonate) and other perfluorinated compounds in rats, indicating that these compounds were found in liver and serum samples after exposure to certain carpet and upholstery protector products that 3M has phased out.
|
2004 |
AR226-1874
|
peG39Q9DkqVJyw1KmDYQ15o2B |
1 |
|
The document is a correspondence from DuPont Fluoroproducts regarding monitoring data related to PFOA, submitted in compliance with the PFOA Users Letter of Intent, indicating ongoing compliance efforts and data reporting.
|
2004 |
AR226-1875
|
a4K9p4yMxbVRv7b92yJ7zypJe |
1 |
|
The document outlines monitoring and reduction efforts for PFOA by Daikin America in Decatur, AL, detailing wastewater and sludge monitoring results, with a focus on identifying sources and implementing measures to reduce PFOA releases into the environment.
|
2004 |
AR226-1878
|
wDZzxGLNqoZbRo6XbxXaBjnko |
24 |
|
The document is a letter from the Haskell Laboratory for Health and Environmental Sciences to the EPA's Office of Pollution Prevention and Toxics, expressing appreciation for a meeting to review DuPont's work related to PFOA and telomers.
|
2004 |
AR226-1879
|
0Yzzd82K02eeeOZM6kboYGmO |
1 |
|
The document presents an overview of DuPont's research and publications related to Ammonium Perfluorooctanoate (APFO) and telomers, including studies on toxicology, human biomonitoring, and environmental effects, as presented to the US EPA by Robert W. Rickard, Ph.D.
|
2004 |
AR226-1880
|
Eq0zzeVeQYq2G5JxVo2JagODR |
56 |
|
The document is a submission from DuPont's legal counsel to the EPA, reporting that an analytical study by the West Virginia Department of Environmental Protection found no detectable levels of perfluorooctanoic acid (PFOA) in fish samples collected near the Belleville Lock and Dam.
|
2004 |
AR226-1882
|
gDB2mz6aNpN4yGoy7qeoVBR5Q |
2 |
|
The document is a correspondence from DuPont's Haskell Laboratory discussing ongoing research related to perfluorinated compounds, specifically mentioning the analysis of samples for PFOA and indicating that a report on the findings will be submitted.
|
2004 |
AR226-1884
|
MJZkR5xZbO1RVXLgBLnLQea4j |
1 |
|
The document is an analytical report from Exygen Research detailing the analysis of perfluorooctanoic acid (PFOA) in fish samples collected by the West Virginia Department of Environmental Protection, indicating the methodology and preparation for testing the samples.
|
2004 |
AR226-1883
|
dYyDXwZ03j2Kgd9rRExwdmwLb |
52 |
|
The document is a submission from the Telomer Research Program, including companies like DuPont and Daikin, to the EPA, providing an updated guidance document on best analytical practices for studies related to perfluorinated compounds.
|
2004 |
AR226-1887
|
oDe8gMOv2rEko20Qzw2jwyagE |
1 |
|
The document provides guidance on best analytical practices for studies related to non-volatile fluorinated compounds, emphasizing the importance of method validation and contamination prevention in the Telomer Research Program sponsored by companies including Asahi Glass Co., Ltd. and DuPont Chemical Solutions Enterprise.
|
2004 |
AR226-1888
|
0v79mRgx8kkjrdgLVrRLxXZR |
8 |
|
The document is a submission from the Telomer Research Program, representing companies including DuPont and Daikin Industries, to the EPA, providing a study report on "(14C)-8-2 Telomer B Alcohol: Adsorption/Desorption using a Batch Equilibrium Method" for inclusion in the administrative record.
|
2004 |
AR226-1889
|
EBR09X3knndyrJdYvQnmV8pb |
1 |
|
The document reports on a study conducted by Covance Laboratories to determine the adsorption/desorption characteristics of (14C)-8-2 Telomer B Alcohol (2-perfluorooctylethanol) in various soil types and sediment, following OECD Guideline 106.
|
2004 |
AR226-1890
|
9RVbvovmw3ap3nm2XN3mYRq6 |
8 |
|
The document outlines the agenda and purpose of a technical meeting held by the EPA and DuPont on December 15, 2004, to discuss degradation studies of telomer substances, which are related to perfluorinated compounds.
|
2004 |
AR226-1892
|
Dv79q11Nrv1GKYrNvvj88amEB |
81 |
|
The document presents findings from a health study on reproductive effects and cancer rates in residents exposed to PFOA from a large C8 source, indicating increased PFOA levels correlate with lower testosterone and higher estrogen in male workers, and significantly elevated rates of uterine/cervical cancer among residents compared to expected rates.
|
2004 |
AR226-1894
|
50LOKeZBbBdBxgjajrY12mo2V |
10 |
|
The document reports on a toxicokinetic study conducted by 3M to assess the absorption and metabolism of FC methyl carboxamide (T-7483.1) in rats, specifically measuring the excretion of perfluoroctanoate (PFOA) in urine following oral administration.
|
2004 |
AR226-1896
|
aOL2RxDrr95MEkqGOmkxyqra |
13 |
|
The document details various toxicological studies conducted by 3M on perfluorinated compounds, specifically PFOS and N-EtFOSE, including inter-species comparisons and molecular biology studies in rats and guinea pigs.
|
2004 |
AR226-1901
|
YDayBKMY3VGx2MRk9K9vGLybD |
2 |
|
The document is a final report on a low-level oral toxicokinetic study of perfluorooctanesulfonate (PFOS) conducted by 3M's Medical Department, detailing the serum and liver concentrations of PFOS in rats.
|
2004 |
AR226-1898
|
xdkgErB1bkZ3VnBRqVYGRvp8y |
158 |
|
The document is a final report from 3M's Corporate Toxicology department detailing an inter-species comparison study of the toxicity mechanisms of perfluorooctanesulfonate (PFOS) and ammonium perfluorooctanoate (APFO) in rats and guinea pigs, as well as N-ethyl perfluorooctanesulfonamido ethanol (N-E
|
2004 |
AR226-1902
|
xjDnpgvd29a25B27KkqoZLx9E |
44 |
|
The document is an amended final report from 3M detailing a comparative molecular biology study on various perfluorinated compounds, including PFOS and its metabolite FOSA, conducted on rats and guinea pigs, with a specific focus on clarifying the conclusions regarding FOSA as a metabolite of PFOS.
|
2004 |
AR226-1904
|
QJoL7k2rjeOj4LvQMNB7bvjB4 |
4 |
|
A mortality study of workers at a perfluorooctanesulfonyl fluoride (POSF) manufacturing facility found a significant excess risk of bladder cancer associated with high exposure to perfluorooctanesulfonate (PFOS), prompting further investigation through a questionnaire and medical record validation.
|
2004 |
AR226-1908
|
3NoJBz0N4VBx06anm4x1JoGVy |
29 |
|
The document is a final report from 3M Medical Department detailing a comparative molecular biology study on various perfluorinated compounds, including PFOS, conducted on rats and guinea pigs following oral dosing, with study numbers T-6295.8, T-6316.4, T-6868.2, T-7071.1, and T-7132.1.
|
2004 |
AR226-1903
|
nmMRBqQQVO7DvZ62mgRJ3Za38 |
211 |
|
The document reports on a study conducted by E.I. du Pont de Nemours and Company examining the age effect on plasma concentrations of ammonium perfluorooctanoate (PFOA) in post-weaning rats following oral gavage.
|
2004 |
AR226-1909
|
aDV5JJ5jEBqRVzNgDYbmYJJ4B |
52 |
|
The document is a peer-reviewed study by Peter C. Mann on the two-year oral toxicity and oncogenicity of FC-143 (a perfluorinated compound) in rats, focusing on ovarian effects.
|
2004 |
AR226-1921
|
e7VLbXVXRMY27EjQLRnBZMMnm |
15 |
|
The document is a submission of a study report on "8-2 Telomer B Alcohol: Developmental Toxicity Study in Rats" by the Telomer Research Program, which includes member companies such as DuPont, to the EPA for inclusion in the administrative record.
|
2004 |
AR226-1938
|
p2B5Vykk7ydGaRzx6pG8GQ2bj |
1 |
|
A mortality study of workers at a perfluorooctanesulfonyl fluoride (POSF) manufacturing facility found a significant excess risk of bladder cancer associated with high exposure to perfluorooctanesulfonate (PFOS), prompting further investigation through a questionnaire and medical record validation among the cohort.
|
2004 |
AR226-1954
|
1g3yMzzdOMwYD9rrqqO1mDn4q |
29 |
|
The document is an analytical report from AXYS Analytical Services detailing the detection of various perfluorinated compounds, including PFOA, in a water sample collected on November 22, 2004, with specific concentration values and detection limits provided.
|
2004 |
AR226-1959
|
NZ5OV5Oe6Og9pNEZVwEV7MQ8 |
10 |
|
The analysis report from AXYS Analytical Services indicates that PFOA was found at a concentration of 1.61 ng/g and PFOS at 5.60 ng/g in solid samples collected on November 24, 2004.
|
2004 |
AR226-1961
|
Dd0yxp96M9K4JR4NBzJO2483N |
29 |
|
This document communicates a change in the C-8 (perfluorooctanoic acid, PFOA) air monitoring program for TEFLON personnel, indicating a reduction in personal and area sampling frequency based on high levels of previous monitoring, while initiating a characterization study of job classifications with C-8 exposure to determine necessary sampling.
|
2004 |
AR226-2004
|
yrjJrM6Yxo2j1Q7Br0pbrEnyD |
1 |
|
3M submitted a TSCA 8(e) substantial risk notice to the EPA regarding a fluorochemical salt, indicating that an acute oral toxicity study in rats revealed potential neurotoxic effects, with an established oral LD50 of 200-2000 mg/kg, as the company investigates its use as a surfactant in semiconductor processing.
|
2004 |
AR226-1778
|
ybmdYL5OG3rZRVqb1DrJRLMEn |
2 |
|
3M submitted a compact disc (CD No. 6) to the EPA containing studies on perfluorooctane sulfonates and related compounds, continuing their voluntary data sharing and dialogue regarding fluorochemicals.
|
2004 |
AR226-1780
|
4aryONBErGQ22Dqdy60rZdQeG |
1 |
|
This is a study report from NOTOX B.V. assessing the acute oral toxicity of T-7868 in rats, completed on April 20, 2004, under project identification NOTOX Project 389598.
|
2004 |
AR226-1779
|
QJ0pE28njGeRnwR6jrZ6Ev55E |
15 |
|
This correspondence from Taft, Stettinius & Hollister LLP to the EPA discusses the PFOA ECA process and includes documents obtained from DuPont related to PFOA degradation studies, while noting that some documents are confidential and cannot be shared.
|
2004 |
AR226-1782
|
XOxpo5GMMEZ0O0evODK9o7xxJ |
3 |
|
3M submitted a TSCA 8(e) supplemental report indicating that a 90-day inhalation study in rats showed perfluorooctanesulfonyl fluoride (POSF) metabolizes to perfluorooctane sulfonate (PFOS), while perfluorooctanoate (PFOA) was detected as a manufacturing residual but not as a metabolite of
|
2004 |
AR226-1800
|
aBp9On76MgR6dq4X4k9bDd9aa |
2 |
|
This is a letter from Asahi Glass Co., Ltd. dated July 9, 2004, addressing Mr. Lynch regarding the GPC chromatographic analysis results.
|
2004 |
AR226-1801
|
4JX1bE9LqgBR7aj8B969Oe05a |
2 |
|
Asahi Glass Co., Ltd. conducted a characterization study of a polymeric product (AAA) which included measurements of total organic fluorine and PFOA content, using various analytical methods to assess its composition.
|
2004 |
AR226-1802
|
YjJ0n0dK2L848kBMOnMKo4ajD |
20 |
|
3M submitted a TSCA 8(e) substantial risk notice to the EPA regarding a protective material after a four-hour acute inhalation study in rats revealed significant respiratory issues and fatalities, despite an exposure assessment indicating minimal risk when the product is used as directed.
|
2004 |
AR226-1804
|
yOm3L2L3JLV3EmNL61R9pvM2 |
3 |
|
3M submitted a TSCA 8(e) substantial risk notice to the EPA regarding a protective material, detailing a four-hour acute inhalation toxicity study in rats that resulted in breathing abnormalities, body weight loss, and the death of four animals after exposure to the test substance vapor.
|
2004 |
AR226-1805
|
n9ooY3qE9v7D3x4p1e4oYpgL6 |
5 |
|
This document is a submission of groundwater and wastewater monitoring data related to perfluorooctanoic acid (PFOA) from 3M's manufacturing sites in Cottage Grove, MN, and Decatur, AL, as required by the Letters of Intent (LOIs) dated March 2003, highlighting ongoing monitoring efforts following the phase-out of PFOA production.
|
2004 |
AR226-1808
|
omYw0gkRGDMowDM3Nmow9xYbg |
9 |
|
The document provides an estimate of the quantities of Aqueous Film Forming Foam (AFFF) in the United States, highlighting the phaseout of PFOS-containing AFFF by 3M and the distinction between ECF-based and telomer-based AFFFs, as commissioned by the Fire Fighting Foam Coalition.
|
2004 |
AR226-1807
|
w9EdxpOaKxdYMXgGvZeVK5zV |
45 |
|
3M submitted a TSCA Section 8(e) Supplemental Notice to the EPA regarding studies on the metabolism of perfluorooctane sulfonyl fluoride (POSF)-based compounds, noting that perfluorooctanesulfonate (PFOS) is the ultimate degradation product of these compounds, which 3M phased out of commercial production in 2002.
|
2004 |
AR226-1809
|
yrv7zQDOrYjM80LmOn2JjD5aX |
3 |
|
The document is an amended final report from 3M's Corporate Toxicology department detailing a study on the comparative molecular biology of various perfluorinated compounds, including PFOS, and their metabolites in rats and guinea pigs, with a specific amendment to the conclusion regarding FOSA as a metabolite of PFOS.
|
2004 |
AR226-1813
|
9LQoB6Y0Ybap7mOm8GbML93d7 |
4 |
|
The document is a final report from 3M's Medical Department detailing a comparative molecular biology study of various perfluorinated compounds, including PFOS, conducted on rats and guinea pigs following oral dosing.
|
2004 |
AR226-1811
|
RjzgMgzz92KbO5Bkbxbp069Ra |
74 |
|
3M submitted final reports on reproductive avian toxicity studies for perfluorooctanesulfonate (PFOS) in northern bobwhite quail and mallard ducks, indicating that PFOS may have accelerated post-reproductive phase regression effects compared to untreated birds, along with analytical reports and toxicological summaries.
|
2004 |
AR226-1815
|
JNrmqRZ6y36noagq6V1gxne2r |
1 |
|
The document is an index of TSCA Section 8(e) docket submissions by 3M Company detailing various toxicological studies and analytical reports on potassium perfluorooctanesulfonate (PFOS) involving Northern Bobwhite quail and Mallard ducks.
|
2004 |
AR226-1816
|
Qg5ObYv0OkLk5r3q1NrGGMzp8 |
2 |
|
The document is a final report from 3M's Corporate Toxicology department detailing an inter-species comparison study of the toxicity mechanisms of perfluorooctanesulfonate (PFOS) and ammonium perfluorooctanoate (APFO) in rats and guinea pigs, conducted between 1997 and 1998.
|
2004 |
AR226-1814
|
kDLmwwod8EpQv4BKaDRe2erKE |
45 |
|
The document is an analytical phase report for a reproduction study on PFOS conducted with the Northern Bobwhite by 3M Environmental Laboratory, detailing compliance with TSCA GLP standards and noting exceptions in data collection and stability assessments.
|
2003 |
AR226-1832
|
QgxRqDKav4g7YaOy0q3bM297L |
4 |
|
The document details a study conducted by Exygen Research for 3M Environmental Technology and Safety Services on the extraction of potassium perfluorooctanesulfonate (PFOS) from red blood cells and serum using HPLC-Electrospray/Mass Spectrometry, ensuring compliance with EPA Good Laboratory Practice Standards.
|
2003 |
AR226-1833
|
2RvQXRDLNdYLQGN85LMxRgB9N |
98 |
|
The document details a study conducted by Exygen Research for 3M Environmental Technology and Safety Services on the extraction of potassium perfluorooctanesulfonate (PFOS) from red blood cells and serum using HPLC-Electrospray/Mass Spectrometry, ensuring compliance with US EPA Good Laboratory Practice Standards.
|
2003 |
AR226-1857
|
OJa7Vr2D1XV1qp5MOXgg20R6K |
98 |
|
The document is a Biennial Report submitted by DuPont for the year 2003 detailing emissions of perfluorooctanoic acid (PFOA) from its Washington Works facility, which reported 5,866 pounds emitted to air, 4,321 pounds discharged to water, and 41,503 pounds managed as waste.
|
2003 |
AR226-1877
|
pBNVqjxap5pwLjLpr2wN53gMa |
2 |
|
The document is a review of proliferative lesions in the exocrine pancreas of rats from two chronic feeding studies involving ammonium perfluorooctanoate (PFOA) conducted by DuPont.
|
2003 |
AR226-1920
|
7xy8w51EG05G37d6qVeyQzK6 |
8 |
|
The document outlines a review of the C-8 (perfluorooctanoic acid, PFOA) control program, emphasizing the need for environmental monitoring outside the plant boundaries and detailing specific administrative controls, protective equipment audits, and blood testing protocols for employees potentially exposed to C-8.
|
2003 |
AR226-2003
|
DMkb0d70j26L8MVV84v5bZpgN |
3 |
|
The document is an analytical phase report for a reproduction study on PFOS conducted by 3M Environmental Laboratory, initiated on February 19, 2002, and compliant with TSCA GLP standards, noting some exceptions in data collection and sample stability.
|
2002 |
AR226-1837
|
8RQrdQK1Nmw0BjkYrzqG9mggK |
10 |
|
The document is a biennial report submitted by DuPont Company for the manufacture of ammonium perfluorooctanoate (APFO) during the calendar years 2002 and 2003, detailing production volume, emissions, groundwater and surface water monitoring results, workplace hygiene, and employee blood monitoring as part of their commitments to the EPA regarding perfluorooctanoic acid (
|
2002 |
AR226-1876
|
Z4G8k6bV8XEwyVm5X3Ya5xRxY |
5 |
|
The document is an Analytical Phase Report for a reproduction study on PFOS conducted by 3M Environmental Laboratory, detailing compliance with TSCA GLP standards and noting exceptions in data collection and sample stability.
|
2002 |
AR226-1861
|
Rjj1ZboJMEMonjy9M3abGa27X |
216 |
|
The document is a draft report by Mark H. Russell from DuPont discussing the modeling of leaching potential for mobile and persistent chemicals, using the USEPA Pesticide Root Zone Model (PRZM) to estimate potential groundwater concentrations following chemical application in Washington County, OH.
|
2002 |
AR226-1799
|
71MxkerzM82drpa3p6y1K7eVe |
8 |
|
The document details a study conducted by Centre Analytical Laboratories, Inc. for 3M Environmental Technology and Safety Services on the extraction of potassium perfluorooctanesulfonate (PFOS) from quail serum and liver using HPLC-Electrospray/Mass Spectrometry, ensuring compliance with EPA Good Laboratory Practice Standards.
|
2001 |
AR226-1819
|
bBmmyK9RrLr0dGVXoRLZDjMyO |
102 |
|
The document details a study conducted by Centre Analytical Laboratories, Inc. for 3M Environmental Technology and Safety Services on the extraction of potassium perfluorooctanesulfonate (PFOS) from egg components for analysis using HPLC-Electrospray/Mass Spectrometry, noting compliance with EPA Good Laboratory Practice Standards despite some exceptions.
|
2001 |
AR226-1820
|
bBGjz4NEXZqNRpJZ896pO6a7Z |
101 |
|
The document details a study conducted by Centre Analytical Laboratories, Inc. for 3M Environmental Technology and Safety Services on the extraction of potassium perfluorooctanesulfonate (PFOS) from mallard serum and liver using HPLC-Electrospray/Mass Spectrometry, ensuring compliance with Good Laboratory Practice standards.
|
2001 |
AR226-1823
|
qarw7Y3BOJdnM1VrMLJzN4N8n |
104 |
|
The document is a laboratory report from 3M Environmental Technology & Safety Services detailing a PFOS dietary LC50 study in northern bobwhite birds, which found that while PFOS levels in liver tissues were consistent across dose groups, sera levels exhibited significant variability among individual animals.
|
2001 |
AR226-1826
|
jmze3oRJ3zY4jkv1mYG8q37V9 |
16 |